Beijing’s BeiGene will collaborate with Myriad Genetics to develop a companion diagnostic to BeiGene’s novel PARP inhibitor, BGB-290. BeiGene will use two of Myriad’s diagnostic tests, myChoice® HRD and BRACAnalysis CDx®, to identify patients most likely to benefit from BRB-290. In 2016, BeiGene started a dose escalation Phase Ia trial of the candidate in Australia. China and the US have also approved Phase I trials of the drug. The companies did not release further terms of the agreement.
